Glatiramer acetate depot for multiple sclerosis [TS ID 10620]
Status ...
Search results
26 results
-
-
Nitisinone for treating alkaptonuria [ID2691]
The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal ...
-
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]
Status ...
-
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]
Status ...
-
Dupilumab for children with severe atopic dermatitis [TS ID 10434]
Status ...
-
Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TS ID 10723]
Status ...
-
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]
Status ...
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (Review of TA573) [ID4057]
Status ...
-
ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria TS ID 10250
Status ...
-
Macitentant–tadalafil for treating pulmonary arterial hypertension TS ID 10517
Status ...
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Dulaglutide for treating type 2 diabetes in children and young people TS ID 10660
Status ...
-
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726
Status ...
-
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]
Status ...
-
Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over TS ID 10761
Status ...
-
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]
Status ...
-
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]
Status ...
-
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]
Status ...
-
Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030]
Status ...
-
Pembrolizumab for previously treated solid tumours with high microsatellite instability or mismatch repair deficiency [ID4036]
Status ...
-
PB006 for multiple sclerosis
Status ...
-
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis [ID3787]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2022.